News coverage about Catabasis Pharmaceuticals (NASDAQ:CATB) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Catabasis Pharmaceuticals earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 44.770039841905 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of Catabasis Pharmaceuticals (CATB) traded down $0.02 during midday trading on Tuesday, hitting $1.55. The stock had a trading volume of 163,000 shares, compared to its average volume of 287,860. The firm has a market capitalization of $35.79 and a PE ratio of -1.03. Catabasis Pharmaceuticals has a twelve month low of $1.08 and a twelve month high of $5.51.
Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.02. The company had revenue of $0.25 million during the quarter. equities research analysts predict that Catabasis Pharmaceuticals will post -1.37 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Catabasis Pharmaceuticals (CATB) Receives Coverage Optimism Score of 0.15” was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.com-unik.info/2018/01/09/catabasis-pharmaceuticals-catb-receives-coverage-optimism-score-of-0-15.html.
About Catabasis Pharmaceuticals
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
What are top analysts saying about Catabasis Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Catabasis Pharmaceuticals and related companies.